Fresenius Launches €200 Million Fund to Propel Healthcare Innovations Forward
In a remarkable move to bolster its presence in the healthcare innovation landscape, Fresenius has declared the establishment of Fresenius Ventures, a corporate venture capital fund with an investment ambition surpassing €200 million over the next five years. This strategic initiative aims to enhance accessibility to innovation networks while leveraging the company's existing expertise in (Bio)Pharma, MedTech, and Care Provision sectors.
Fresenius Ventures will actively invest in pioneering founders, cutting-edge technologies, and emerging business models, ranging from initial funding phases to growth stages. This newly formed unit is a fusion of venture financing and comprehensive knowledge in medical, regulatory, and operational domains. It is designed to provide access to valuable clinical, scientific, and academic networks, simultaneously fostering the company’s innovation capacity within the healthcare ecosystem.
Michael Sen, CEO of Fresenius, emphasized the significance of this venture, stating, “Fresenius Ventures is a strategic instrument of #FutureFresenius. Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent.”
The potential investment sectors for Fresenius Ventures are expansive, covering areas like precision nutrition, microbiome research, new treatment modalities, and digital healthcare solutions. Each investment will be aligned with Fresenius’ capital allocation strategy, aiming for sustainable growth.
Business expert Dr. Thomas Michael Thestrup has been appointed to oversee Fresenius Ventures. With extensive experience in the healthcare venture capital sphere, having previously worked with Angelini Ventures, he brings a wealth of knowledge to the position. Dr. Thestrup remarked, “Fresenius Ventures backs the innovators shaping the next era of healthcare with...deep operating and regulatory expertise.” His diverse background in research and health technology, coupled with a Ph.D. from the renowned Max Planck Institute, positions him well to lead this venture.
Fresenius, a global leader in healthcare dedicated to improving and saving lives, provides a vast array of services through its subsidiaries, Fresenius Kabi and Fresenius Helios. Each year, Fresenius Kabi reaches around 450 million patients with its essential medicines and clinical nutrition, while Fresenius Helios operates as Europe’s largest private hospital operator, treating approximately 27 million patients annually.
With this ambitious venture fund, Fresenius solidifies its commitment to not only enhancing its core offerings but also embracing innovation for future healthcare challenges. The €200 million investment mark is a significant milestone that illustrates Fresenius' dedication to evolving within the healthcare landscape. The company, boasting over 178,000 employees operating in more than 60 countries, generated an impressive revenue of €22.6 billion in 2025, reinforcing its status as a pivotal player in global healthcare.
To learn more about Fresenius Ventures and how it plans to stimulate healthcare innovation, interested parties can visit their website at Fresenius Ventures.
Fresenius Ventures will actively invest in pioneering founders, cutting-edge technologies, and emerging business models, ranging from initial funding phases to growth stages. This newly formed unit is a fusion of venture financing and comprehensive knowledge in medical, regulatory, and operational domains. It is designed to provide access to valuable clinical, scientific, and academic networks, simultaneously fostering the company’s innovation capacity within the healthcare ecosystem.
Michael Sen, CEO of Fresenius, emphasized the significance of this venture, stating, “Fresenius Ventures is a strategic instrument of #FutureFresenius. Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent.”
The potential investment sectors for Fresenius Ventures are expansive, covering areas like precision nutrition, microbiome research, new treatment modalities, and digital healthcare solutions. Each investment will be aligned with Fresenius’ capital allocation strategy, aiming for sustainable growth.
Business expert Dr. Thomas Michael Thestrup has been appointed to oversee Fresenius Ventures. With extensive experience in the healthcare venture capital sphere, having previously worked with Angelini Ventures, he brings a wealth of knowledge to the position. Dr. Thestrup remarked, “Fresenius Ventures backs the innovators shaping the next era of healthcare with...deep operating and regulatory expertise.” His diverse background in research and health technology, coupled with a Ph.D. from the renowned Max Planck Institute, positions him well to lead this venture.
Fresenius, a global leader in healthcare dedicated to improving and saving lives, provides a vast array of services through its subsidiaries, Fresenius Kabi and Fresenius Helios. Each year, Fresenius Kabi reaches around 450 million patients with its essential medicines and clinical nutrition, while Fresenius Helios operates as Europe’s largest private hospital operator, treating approximately 27 million patients annually.
With this ambitious venture fund, Fresenius solidifies its commitment to not only enhancing its core offerings but also embracing innovation for future healthcare challenges. The €200 million investment mark is a significant milestone that illustrates Fresenius' dedication to evolving within the healthcare landscape. The company, boasting over 178,000 employees operating in more than 60 countries, generated an impressive revenue of €22.6 billion in 2025, reinforcing its status as a pivotal player in global healthcare.
To learn more about Fresenius Ventures and how it plans to stimulate healthcare innovation, interested parties can visit their website at Fresenius Ventures.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.